Magazine Article | November 1, 2022

Companies To Watch: iTolerance

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation

iTolerance is in early development of a drug treatment that would eliminate the need for immunosuppression in implantation of islet cells to secrete insulin in patients with Type 1 diabetes. The treatment, coded iTOL- 100, suppresses activated T cells that would otherwise cause immune rejection of the transplanted cells. It does so by binding to the Fas receptor (FasR) on the activated T cells, causing them to die by apoptosis. iTolerance has completed mouse and non-human primate testing on the treatment with positive results. Other organ transplant programs, such as for the liver, are underway or under consideration.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader